Heart Failure, Congestive Clinical Trial
— MyROADOfficial title:
My Recordable On-Demand Audio Discharge Instructions (MyROAD)
NCT number | NCT02901314 |
Other study ID # | 16-122 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2016 |
Est. completion date | March 30, 2022 |
Verified date | August 2022 |
Source | The Cleveland Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-adherence to the heart failure (HF) plan of care after hospital discharge has been associated with clinical outcomes, including the combined endpoint of all-cause mortality and rehospitalization for decompensated HF. Patients and informal caregivers receive education materials but may not act due to multiple factors. A recorded message that could be repeatedly played by patients and caregivers might increase adherence to post-discharge self-care behaviors and early follow-up appointments, and have clinical benefits related to a reduction in all-cause mortality and rehospitalization. The purposes of this randomized, controlled study are to examine the effects of use of a novel MyROAD (Recordable On-Demand Audio Discharge) card, given to patients at discharge. The aims of this single-blind, placebo-controlled study are to examine the effects of recorded messages that can be replayed post discharge (delivered via the MyROAD card) on multiple subjective and objective clinical outcomes.
Status | Completed |
Enrollment | 1073 |
Est. completion date | March 30, 2022 |
Est. primary completion date | September 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Not referred for cardiac transplantation or ventricular assist device during the index hospitalization, - Minimum age 18 years (no upper age limit), - Ability to read and write, - Discharge to home or to a family member's home and has control of making self-care decisions, - Willing to participate; which requires three (3) follow-up telephone calls post-discharge. Exclusion Criteria: - Chart documented psychiatric or cognitive conditions that limit ability to understand or adhere to self-care recommendations (Alzheimer's condition, dementia, schizophrenia, other neurological history that impairs memory), - Plans to discharge to assisted living apartment/center, skilled nursing facility or hospice care center, - Receiving home hospice or palliative care; or has a medical condition reflecting less than 1 year of survival (cachexia, end stage liver disease or cancer or non-ambulatory New York Heart Association functional class IV heart failure), - Post-cardiac transplantation or ventricular assist device placement, - Currently enrolled in another experimental HF research study, - Chronic renal failure and receiving chronic hemodialysis therapy for an estimated glomerular filtration rate < 30 mL/minute/1.73 m2, - A non-traditional form of HF (hypertrophic or restrictive forms of cardiomyopathy, congenital heart disease or Takotsubo cardiomyopathy). - Wheelchair bound, uses a cane or walker, or unable to carry out physical activity, including walking,due to a chronic disability or documented medical condition. |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Fairview Hospital | Cleveland | Ohio |
United States | Cleveland Clinic main campus | Cleveland | Ohio |
United States | Cleveland Clinic Hillcrest hospital | Mayfield Heights | Ohio |
United States | Cleveland Clinic Medina Hospital | Medina | Ohio |
Lead Sponsor | Collaborator |
---|---|
The Cleveland Clinic | American Greetings |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | heart failure rehospitalization | Chart review; interviews | 30 day | |
Secondary | time to first occurrence of HF-related hospitalization, ED visit or death/ cardiac transplantation/ventricular assist device(composite outcome) | chart review; interviews | time to first occurrence up to 30 days | |
Secondary | functional status | Duke Activity Status Index (telephone call) | 45 day | |
Secondary | perceived adherence to activity recommendations | investigator developed tool; used in previous research (telephone call) | 45 day | |
Secondary | 7-day follow-up appointment with the healthcare provider assigned before discharge | chart review; interview (telephone call) | 45 day | |
Secondary | all cause re-hospitalization or ED visit or death or cardiac transplantation/ventricular assist device (composite outcome) | chart review; interview (telephone call) | 180 days | |
Secondary | all cause re-hospitalization or ED visit or death or cardiac transplantation/ventricular assist device (composite outcome) | chart review; interview (telephone call) | 30 days | |
Secondary | all cause re-hospitalization or ED visit or death or cardiac transplantation/ventricular assist device (composite outcome) | chart review; interview (telephone call) | 90 day | |
Secondary | quality of life (health status) | Kansas City Cardiomyopathy Questionnaire; telephone call | 45 day | |
Secondary | Symptoms of HF | investigator developed tool; used in previous research; telephone call | 45 day | |
Secondary | time to first occurrence of all-cause hospitalization, ED visit or death/ cardiac transplantation/ventricular assist device (composite outcome) | chart review; interview (telephone call) | time to first occurrence up to 180 days | |
Secondary | heart failure re-hospitalization | chart review; interview (telephone call) | 180 day | |
Secondary | heart failure re-hospitalization | chart review; interview (telephone call) | 90 day | |
Secondary | time to first occurrence of all-cause hospitalization, ED visit or death/ cardiac transplantation/ventricular assist device (composite outcome) | chart review; interview (telephone call) | time to first occurrence up to 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |